Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 847 results for "ranbaxy"

M & A On Their Mind?
Financial Express

M & A On Their Mind?

Sun Pharma recently completed its acquisition of Ranbaxy. It has also set aside a record $7 billion for further acquisitions. And its not the only one, pharma companies are scouting for suitable targets to expand their product baskets and enter new ... Financial Express, 1 day ago

34 images for ranbaxy

Financial Express, 1 day ago
Nikkei Asian Review, 5 days ago
India Infoline, 6 days ago
RSC, 1 week ago
Mangalorean, 4 weeks ago
PR inside, 3 weeks ago
VC Circle, 1 month ago
New Indian Express, 1 month ago
Rediff.com, 1 month ago
NDTV Profit, 1 month ago
India Infoline

Top Pharma news of the day

Aurobindo Pharma has appointed Sanjeev Dani, former senior executive with Ranbaxy Laboratories, as chief operating officer and head of formulation business. The company announced the appointment on Tuesday in a call with investors while declaring its results ...
 India Infoline6 days ago Aurobindo appoints former Ranbaxy executive Sanjeev Dani as COO  Economic Times1 week ago After acquiring Ranbaxy for $3.2 bn, Sun Pharma cuts staff in R&D division  Economic Times1 month ago More cuts as Sun Pharma pulls Ranbaxy into the fold  FiercePharmaManufacturing1 month ago
[x]  
Nikkei Asian Review

Ranbaxy a bitter pill for Sun Pharma

NEW DELHI -- India's Sun Pharmaceutical Industries is finding it harder than expected to integrate with former rival, Ranbaxy Laboratories, which it bought from Japan's Daiichi Sankyo for $4 billion in March. Close Dilip Shanghvi Reuters ...
 Nikkei Asian Review6 days ago Triage the plan as India's Sun moves on troubled Ranbaxy plants  Fierce Biotech IT1 month ago Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market  FiercePharmaManufacturing1 month ago Focus on getting Ranbaxy's plants USFDA nod one at a time: Sun Pharma  Economic Times2 months ago
DNA

Sun Pharma slumps after Q1 net profit falls

A drop in US sales and the integration of Ranbaxy Laboratories weighed on its financial performance. The nation's top drug maker took a Rs 685 crore charge related to the integration of Ranbaxy, which formally became part of Sun in March this year. Sales rose ...
 Economic Times2 weeks ago Slowdown in US sales, Ranbaxy integration weigh on Sun Pharma  Economic Times3 weeks ago Sun Pharma Q1 profit tanks 46% on Ranbaxy integration cost  Money Control3 weeks ago Sun Pharma drops 15% as its profit seen hit on Ranbaxy integration  DNA1 month ago
[x]  
Rediff.com

Shanghvi all set to turn around Ranbaxy

The soft-spoken billionaire pharmaceutical tycoon Dilip Shanghvi is well known as Harry Potter fan. Shanghvi, who started Sun Pharma as a two man operation, now employs 14,000 employees, with products reaching over 40 countries. With the help of 13 acquisitions, over the last 22 years, Shanghvi has built Sun Pharmaceuticals into India’s largest pharmaceutical company, with consolidated sales of over Rs 27,500 crore. But with his latest acquisition of Ranbaxy, Shanghvi will perhaps need a ...
 Rediff.com1 month ago Shanghvi moves into top gear to turnaround Ranbaxy  Smart Investor1 month ago Dilip Shanghvi moves into top gear to turn around Ranbaxy  Rediff.com1 month ago
[x]  
Times of India

Sun Pharma mulling options of exiting Ranbaxy's "low-margin" overseas geographies

We encourage visitors to register on IIFL. Registering on the site is absolutely Free and offers you the following benefits. Free Portfolio of Equity and Assets Exclusive E-newsletter Post Comments and Share Feedback Your Personal Page Access Premium Services ...
 India Infoline1 month ago Sun Pharma may exit part of Ranbaxy business to push growth  Economic Times1 month ago Sun Pharma may shed part of Ranbaxy biz to push growth  Times of India1 month ago

Sun Pharma tumbles as Ranbaxy merger cost to impact revenues, profit

Sun Pharmaceutical Industries , an international, integrated, speciality pharmaceutical company, witnessed a sharp fall in share price on Tuesday after the company said that the company's FY16 revenue could remain flat or show a decline over FY15 ...
 MyIris1 month ago Sun Pharma tumbles as Ranbaxy integration charges to impact revenues, profit  Myiris1 month ago

Sun Pharmaceutical to discontinue certain non-strategic businesses of Ranbaxy

SENSEX 28434.66 14.54 0.05% NIFTY 8606.95
 Finalaya.com1 month ago Sun may divest Ranbaxy's non-strategic businesses  Hindu Business Line1 month ago India : CERTAIN non-strategic businesses of Ranbaxy to be discontinue by Sun Pharmaceutical [TendersInfo (India)]  Pharmacy Choice1 month ago Sun may divest Ranbaxys non-strategic businesses  FirstWord Pharma1 month ago

Ranbaxy integration may hurt Sun Pharma's Q1 earnings

According to average of estimates of analysts polled by CNBC-TV18, net profit is seen rising 0.6 percent sequentially to Rs 894 crore and revenue may increase 1.7 percent to Rs 6,262 crore in the quarter ended June.
 Money Control3 weeks ago

RIL, BPCL, NTPC and Ranbaxy to see some action today

You are here ยป Indian-Commodity : Top News : 19-Nov 2013 Reliance Industries (RIL) will have to provide a bank guarantee of $135 million every quarter to get a higher price for natural gas from April 1 next year. The bank guarantee will be ...
 Indian-Commodity4 weeks ago ONGC, Engineers India and Coal India to see some action today  Indian-Commodity4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less